Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 2
1979 2
1982 1
1984 1
1993 1
1994 3
1995 5
1997 1
1999 2
2000 1
2001 5
2002 6
2003 3
2004 2
2005 1
2006 3
2007 2
2008 2
2009 2
2010 7
2011 12
2012 7
2013 10
2014 8
2015 8
2016 5
2017 10
2018 4
2019 10
2020 10
2021 12
2022 10
2023 8
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. Among authors: sandhu sk. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: sandhu sk. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Ventricular function.
Greenberg SB, Sandhu SK. Greenberg SB, et al. Among authors: sandhu sk. Radiol Clin North Am. 1999 Mar;37(2):341-59, vi. doi: 10.1016/s0033-8389(05)70098-1. Radiol Clin North Am. 1999. PMID: 10198647 Review.
Rat Bite Erosion of the Knee.
Kwok TSH, Sandhu SK. Kwok TSH, et al. Among authors: sandhu sk. J Rheumatol. 2023 Aug;50(8):1087. doi: 10.3899/jrheum.221171. Epub 2023 Feb 15. J Rheumatol. 2023. PMID: 36792114 No abstract available.
MicroRNA expression signatures in solid malignancies.
Galasso M, Sandhu SK, Volinia S. Galasso M, et al. Among authors: sandhu sk. Cancer J. 2012 May-Jun;18(3):238-43. doi: 10.1097/PPO.0b013e318258b5f4. Cancer J. 2012. PMID: 22647360 Review.
Interrupted Aortic Arch.
Sandhu SK, Pettitt TW. Sandhu SK, et al. Curr Treat Options Cardiovasc Med. 2002 Aug;4(4):337-340. doi: 10.1007/s11936-002-0013-5. Curr Treat Options Cardiovasc Med. 2002. PMID: 12093390
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A Azad A, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Siva S, et al. Among authors: sandhu sk. Eur Urol. 2022 Apr;81(4):364-372. doi: 10.1016/j.eururo.2021.12.006. Epub 2021 Dec 23. Eur Urol. 2022. PMID: 34953600 Clinical Trial.
Envisioning the future of early anticancer drug development.
Yap TA, Sandhu SK, Workman P, de Bono JS. Yap TA, et al. Among authors: sandhu sk. Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.
Urethral luminal epithelia are castration-insensitive cells of the proximal prostate.
Joseph DB, Henry GH, Malewska A, Iqbal NS, Ruetten HM, Turco AE, Abler LL, Sandhu SK, Cadena MT, Malladi VS, Reese JC, Mauck RJ, Gahan JC, Hutchinson RC, Roehrborn CG, Baker LA, Vezina CM, Strand DW. Joseph DB, et al. Among authors: sandhu sk. Prostate. 2020 Aug;80(11):872-884. doi: 10.1002/pros.24020. Epub 2020 Jun 4. Prostate. 2020. PMID: 32497356 Free PMC article.
157 results